We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pharnext SA (FR0011191287 - ALPHA) (the "Company") today announces its Board of Directors has appointed Piers Morgan as a new, independent, non-executive member following a comprehensive search and selection process.
French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations.